Keep pulling the thread on Endpoints 100.
The latest Endpoints 100 survey reflects the most negative sentiment among biotech and pharma executives that founding editor John Carroll has observed in over two decades.
Approximately 180 public biotech companies are currently trading for less than the value of their cash on hand.
Three out of four biotech executives surveyed in the Endpoints 100 expect that the reorganization of the FDA will have a harmful effect on the industry.
There have been 28 biotech mega-rounds (fundraises of $100 million or more) so far this year, a decrease from 45 at the same point last year.
In the latest Endpoints 100 survey, 58% of biotech executives rated the flow of venture capital investments as "poor," the highest percentage in the survey's nine-year history.
In the Endpoints 100 survey, 85% of respondents believed that removing Peter Marks from his position at CIBER was a "terrible idea."
The administration of Robert F. Kennedy Jr. announced it would remove healthy people and children from the official recommendations for COVID-19 vaccines.
The current downturn in the biotech industry has now lasted for three years, longer than many industry participants had expected.
According to the Endpoints 100 survey, one in ten biotech executives reported experiencing a drug approval delay at the FDA due to staff turnover.
Venture capital investors in biotech are concentrating their capital on existing portfolio companies or a smaller number of new companies, rather than spreading their bets widely as they did in 2020-2021.
In the latest Endpoints 100 survey, zero respondents rated the flow of venture capital investments as "excellent."
The biotech industry is experiencing a continuing R&D decoupling from China, although business development activities between large pharma and Chinese firms continue.